Kainova reports positive results from phase I EPRAD study of DT-9081, an oral EP4 receptor antagonist, in advanced solid tumours: Montreal, Canada Thursday, March 12, 2026, 17:00 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results